Kala Pharmaceuticals Inc (NASDAQ:KALA) Expected to Post FY2021 Earnings of ($1.52) Per Share

Share on StockTwits

Kala Pharmaceuticals Inc (NASDAQ:KALA) – Research analysts at Jefferies Financial Group increased their FY2021 earnings per share estimates for shares of Kala Pharmaceuticals in a research note issued on Monday, September 14th. Jefferies Financial Group analyst B. Amin now expects that the company will post earnings per share of ($1.52) for the year, up from their prior estimate of ($1.56). Jefferies Financial Group currently has a “Hold” rating and a $10.00 price target on the stock. Jefferies Financial Group also issued estimates for Kala Pharmaceuticals’ FY2022 earnings at ($0.73) EPS, FY2023 earnings at $0.05 EPS and FY2024 earnings at $0.58 EPS.

KALA has been the topic of a number of other research reports. JPMorgan Chase & Co. lifted their target price on shares of Kala Pharmaceuticals from $14.00 to $19.00 and gave the company an “overweight” rating in a research note on Wednesday, May 27th. HC Wainwright restated a “buy” rating and set a $17.00 target price (up previously from $14.00) on shares of Kala Pharmaceuticals in a research note on Wednesday, May 27th. Northland Securities restated a “buy” rating and set a $17.00 target price on shares of Kala Pharmaceuticals in a research note on Friday, August 7th. BidaskClub upgraded shares of Kala Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, September 11th. Finally, Oppenheimer assumed coverage on shares of Kala Pharmaceuticals in a research note on Friday, May 29th. They set an “outperform” rating and a $21.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $18.50.

KALA opened at $8.61 on Wednesday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 11.29 and a current ratio of 11.63. Kala Pharmaceuticals has a fifty-two week low of $3.24 and a fifty-two week high of $14.68. The firm’s fifty day moving average is $8.79 and its 200 day moving average is $9.81. The stock has a market cap of $482.68 million, a price-to-earnings ratio of -3.79 and a beta of 0.24.

Kala Pharmaceuticals (NASDAQ:KALA) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.42) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.42). Kala Pharmaceuticals had a negative net margin of 1,993.41% and a negative return on equity of 105.36%.

A number of hedge funds have recently made changes to their positions in the business. RA Capital Management L.P. increased its holdings in shares of Kala Pharmaceuticals by 139.7% in the 1st quarter. RA Capital Management L.P. now owns 10,874,613 shares of the company’s stock worth $95,588,000 after buying an additional 6,337,135 shares during the last quarter. Eventide Asset Management LLC bought a new stake in shares of Kala Pharmaceuticals in the 1st quarter worth about $25,956,000. Orbimed Advisors LLC increased its holdings in shares of Kala Pharmaceuticals by 56.7% in the 1st quarter. Orbimed Advisors LLC now owns 5,402,730 shares of the company’s stock worth $47,490,000 after buying an additional 1,954,890 shares during the last quarter. FMR LLC increased its holdings in shares of Kala Pharmaceuticals by 64.1% in the 2nd quarter. FMR LLC now owns 4,678,383 shares of the company’s stock worth $49,169,000 after buying an additional 1,826,867 shares during the last quarter. Finally, Vivo Capital LLC bought a new stake in shares of Kala Pharmaceuticals in the 1st quarter worth about $6,917,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Kala Pharmaceuticals Company Profile

Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.

Featured Story: Why is cost of goods sold important?

Earnings History and Estimates for Kala Pharmaceuticals (NASDAQ:KALA)

Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Vireo Health International  Receives Buy Rating from Echelon Wealth Partners
Vireo Health International Receives Buy Rating from Echelon Wealth Partners
Bureau Veritas  Upgraded at HSBC
Bureau Veritas Upgraded at HSBC
Q3 2021 EPS Estimates for Shake Shack Inc  Increased by Analyst
Q3 2021 EPS Estimates for Shake Shack Inc Increased by Analyst
Seres Therapeutics Inc  to Post Q3 2020 Earnings of  Per Share, Oppenheimer Forecasts
Seres Therapeutics Inc to Post Q3 2020 Earnings of Per Share, Oppenheimer Forecasts
BJ’s Restaurants, Inc. to Post Q1 2021 Earnings of  Per Share, Piper Sandler Forecasts
BJ’s Restaurants, Inc. to Post Q1 2021 Earnings of Per Share, Piper Sandler Forecasts
William Blair Equities Analysts Lift Earnings Estimates for Scotts Miracle-Gro Co
William Blair Equities Analysts Lift Earnings Estimates for Scotts Miracle-Gro Co


 
© 2006-2020 Zolmax.